web analytics
1.9 C
Munich
Sunday, December 4, 2022

Relief Therapeutics Holding SA (OTCMKTS: RLFTF) Surges Higher as RLF-100 (Aviptadil) Gains Traction

Relief Therapeutics Holding SA (OTCMKTS: RLFTF) is heating up and surging higher on massive volume as its covid-19 treatment RLF-100 (aviptadil) gains serious traction. The drug is currently in advanced clinical trials and recently released compassionate use data is showing compelling results with a number of covid-19 patients on ventilators returning home in only five days after treatment with RLF-100.

Relief Therapeutics is a Swiss Company that trades on the U.S. OTC Exchange in addition to its Swiss Stock Exchange Listing (RLF). RLF-100 is simple to manufacture and cheap to produce at scale and if the clinical trials reflect the compassionate use date, RLF-100 should easily get approval from the FDA.

Relief Therapeutics Holding SA (OTCMKTS: RLFTF) is a Swiss-based publicly-traded drug development company focusing primarily on the clinical development of peptides and proteins of natural or engineered origin to address unmet medical needs. Its expertise covers the entire R&D lifecycle up to market approval. Relief Therapeutics holds orphan drug designations from the U.S. Food and Drug Administration and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis.  Relief Therapeutics also holds a U.S. patent1 for RLF-100 and proprietary manufacturing processes for its synthesis.

Relief Therapeutics holds orphan drug designations from the U.S. Food and Drug Administration and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis.  Relief Therapeutics also holds a U.S. patent1 for RLF-100 and proprietary manufacturing processes for its synthesis.

To Find out the inside Scoop on RLF-100 and Relief Therapeutics Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

RLFTF

Earlier this month Relief Therapeutics and its US partner, NeuroRx, Inc. reported RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19. At the same time, independent researchers have reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes. RLF-100 has been granted Fast Track designation by FDA and is being developed as a Material Threat Medical Countermeasure in cooperation with the National Institutes of Health and other federal agencies. Further research will be conducted.

The first report of rapid clinical recovery under emergency use IND was posted by doctors from Houston Methodist Hospital. The report describes a 54-year-old man who developed COVID-19 while being treated for rejection of a double lung transplant and who came off a ventilator within four days. Similar results were subsequently seen in more than 15 patients treated under emergency use IND and an FDA expanded access protocol which is open to patients too ill to be admitted to the ongoing Phase 2/3 FDA trial.  Patients with Critical COVID-19 were seen to have a rapid clearing of classic pneumonitis findings on x-ray, accompanied by an improvement in blood oxygen and a 50% or greater average decrease in laboratory markers associated with COVID-19 inflammation.2 clinicaltrials.gov NCT04311697.

We have a Monster Pick Coming. Subscribe Right Now!

RLFTF is running northbound in a hurry as its covid-19 treatment; RLF-100 (aviptadil) gains serious traction. The drug is currently in advanced clinical trials and recently released compassionate use data is showing compelling results with a number of covid-19 patients on ventilators returning home in only five days after treatment with RLF-100. Relief Therapeutics is a Swiss Company that trades on the U.S. OTC Exchange. RLF-100 is simple to manufacture and cheap to produce at scale and if the clinical trials reflect the compassionate use date, RLF-100 should easily get approval from the FDA. Microcapdaily first reported on Relief Therapeutics on August 3 when the stock was taking off from $0.04. We will be updating on RLFTF on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with RLFTF.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in RLFTF either long or short and we have not been compensated for this article.

Ali Raza
A journalist, with experience in web journalism and marketing. Ali holds a master degree in finance and enjoys writing about cryptocurrencies and fintech. Ali’s work has been published on a number of cryptocurrency publications.

More articles

1 COMMENT

  1. I took a position on this stock, I believe the treatment will be significant to Covid -19 patients progressing to acute respiratory distress syndrome (ARDS). The moa of aviptdail favors a reduction in cytokine storm and bradykinin storm.

Leave a Reply to Lazaro Dinh Cancel reply

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.